2 active not recruiting. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Ataxia: new trials by email Literature Review of Ataxia trials Research Report on Ataxia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG GLM101 (Part A, Double-blind), Placebo (Part A, Double-blind), GLM101 (Part B, Open-label) - Phosphomannomutase 2 Deficiency, PMM2-CDG | Phase 2 / Phase 3 | Active not recruiting | Glycomine, Inc. | 50 | 2025-07-09 | 2026-08-14 |
| NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia Nicotinamide ribonucleoside - Ataxia Telangiectasia | Phase 2 | Active not recruiting | University Hospital, Akershus | 13 | 2019-06-05 | 2022-08-17 |
Ataxia Telangiectasia (1) · Congenital disorder of glycosylation type 1A (1)
Dyskinesias (2) · Nervous System Diseases (2) · Neurologic Manifestations (2) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Cerebellar Ataxia (1) · Cerebellar Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · DNA Repair-Deficiency Disorders (1) · Genetic Diseases, Inborn (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Metabolic Diseases (1)
Double-Blind Method (1) · nicotinamide-beta-riboside (1)
Glycomine, Inc. (1) · University Hospital, Akershus (1)
Belgium (1) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Norway (1) · Poland (1) · Portugal (1) · Spain (1) · United Kingdom (1) · United States (1)
Hilde L Nilsen (1)